S&P 500   3,377.90 (+1.33%)
DOW   27,917.96 (+0.83%)
QQQ   270.92 (+2.16%)
AAPL   446.95 (+2.16%)
MSFT   207.45 (+2.00%)
FB   261.60 (+2.14%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,143.01 (+2.02%)
NVDA   450.14 (+3.72%)
CGC   17.12 (+1.00%)
BABA   253.43 (+2.02%)
TSLA   1,498.63 (+9.04%)
GE   6.62 (-1.63%)
MU   47.99 (+0.48%)
AMD   81.16 (+5.57%)
T   30.23 (+0.10%)
F   7.16 (-0.97%)
ACB   9.84 (-1.80%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   132.06 (+1.20%)
BAC   27.03 (+0.41%)
BA   178.35 (-0.99%)
S&P 500   3,377.90 (+1.33%)
DOW   27,917.96 (+0.83%)
QQQ   270.92 (+2.16%)
AAPL   446.95 (+2.16%)
MSFT   207.45 (+2.00%)
FB   261.60 (+2.14%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,143.01 (+2.02%)
NVDA   450.14 (+3.72%)
CGC   17.12 (+1.00%)
BABA   253.43 (+2.02%)
TSLA   1,498.63 (+9.04%)
GE   6.62 (-1.63%)
MU   47.99 (+0.48%)
AMD   81.16 (+5.57%)
T   30.23 (+0.10%)
F   7.16 (-0.97%)
ACB   9.84 (-1.80%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   132.06 (+1.20%)
BAC   27.03 (+0.41%)
BA   178.35 (-0.99%)
S&P 500   3,377.90 (+1.33%)
DOW   27,917.96 (+0.83%)
QQQ   270.92 (+2.16%)
AAPL   446.95 (+2.16%)
MSFT   207.45 (+2.00%)
FB   261.60 (+2.14%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,143.01 (+2.02%)
NVDA   450.14 (+3.72%)
CGC   17.12 (+1.00%)
BABA   253.43 (+2.02%)
TSLA   1,498.63 (+9.04%)
GE   6.62 (-1.63%)
MU   47.99 (+0.48%)
AMD   81.16 (+5.57%)
T   30.23 (+0.10%)
F   7.16 (-0.97%)
ACB   9.84 (-1.80%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   132.06 (+1.20%)
BAC   27.03 (+0.41%)
BA   178.35 (-0.99%)
S&P 500   3,377.90 (+1.33%)
DOW   27,917.96 (+0.83%)
QQQ   270.92 (+2.16%)
AAPL   446.95 (+2.16%)
MSFT   207.45 (+2.00%)
FB   261.60 (+2.14%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,143.01 (+2.02%)
NVDA   450.14 (+3.72%)
CGC   17.12 (+1.00%)
BABA   253.43 (+2.02%)
TSLA   1,498.63 (+9.04%)
GE   6.62 (-1.63%)
MU   47.99 (+0.48%)
AMD   81.16 (+5.57%)
T   30.23 (+0.10%)
F   7.16 (-0.97%)
ACB   9.84 (-1.80%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   132.06 (+1.20%)
BAC   27.03 (+0.41%)
BA   178.35 (-0.99%)
Log in

NASDAQ:MGTAMagenta Therapeutics Stock Price, Forecast & News

$7.18
+0.07 (+0.98 %)
(As of 08/12/2020 12:07 PM ET)
Add
Compare
Today's Range
$7.07
Now: $7.18
$7.19
50-Day Range
$7.02
MA: $7.91
$10.30
52-Week Range
$5.76
Now: $7.18
$16.19
Volume1,562 shs
Average Volume226,520 shs
Market Capitalization$346.46 million
P/E RatioN/A
Dividend YieldN/A
Beta2.72
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
Magenta Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.05 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGTA
CUSIPN/A
CIKN/A
Phone857-242-0170

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.62 per share

Profitability

Net Income$-76,770,000.00

Miscellaneous

Employees59
Market Cap$346.46 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$7.18
+0.07 (+0.98 %)
(As of 08/12/2020 12:07 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MGTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions

How has Magenta Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Magenta Therapeutics' stock was trading at $9.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MGTA stock has decreased by 21.6% and is now trading at $7.18.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Magenta Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Magenta Therapeutics
.

When is Magenta Therapeutics' next earnings date?

Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Magenta Therapeutics
.

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics Inc (NASDAQ:MGTA) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.06.
View Magenta Therapeutics' earnings history
.

What price target have analysts set for MGTA?

4 Wall Street analysts have issued 1-year target prices for Magenta Therapeutics' stock. Their forecasts range from $15.00 to $22.00. On average, they expect Magenta Therapeutics' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 164.6% from the stock's current price.
View analysts' price targets for Magenta Therapeutics
.

Has Magenta Therapeutics been receiving favorable news coverage?

Press coverage about MGTA stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Magenta Therapeutics earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Magenta Therapeutics
.

Are investors shorting Magenta Therapeutics?

Magenta Therapeutics saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 1,370,000 shares, a decrease of 6.2% from the July 15th total of 1,460,000 shares. Based on an average daily volume of 315,400 shares, the short-interest ratio is currently 4.3 days. Currently, 5.8% of the company's shares are sold short.
View Magenta Therapeutics' Short Interest
.

Who are some of Magenta Therapeutics' key competitors?

What other stocks do shareholders of Magenta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), Myovant Sciences (MYOV), Nabriva Therapeutics (NBRV), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Crispr Therapeutics (CRSP), ImmunoGen (IMGN), Pfizer (PFE) and AT&T (T).

Who are Magenta Therapeutics' key executives?

Magenta Therapeutics' management team includes the following people:
  • Mr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 48)
  • Mr. Michael P. Cooke, Chief Scientific Officer (Age 57)
  • Ms. Alison Lawton, Board Advisor (Age 58)
  • Mr. Jason Ryan, Chief Operating & Financial Officer (Age 45)
  • Ms. Manisha Pai, VP of Investor Relations & Communications

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Who are Magenta Therapeutics' major shareholders?

Magenta Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Platinum Investment Management Ltd. (0.61%), Asymmetry Capital Management L.P. (0.53%), Monashee Investment Management LLC (0.21%), Alps Advisors Inc. (0.14%), Trexquant Investment LP (0.06%) and State Board of Administration of Florida Retirement System (0.03%). Company insiders that own Magenta Therapeutics stock include Bruce Booth, Jason Gardner, John C Davis Jr and Michael P Cooke.
View institutional ownership trends for Magenta Therapeutics
.

Which major investors are selling Magenta Therapeutics stock?

MGTA stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., and New York State Common Retirement Fund. Company insiders that have sold Magenta Therapeutics company stock in the last year include Jason Gardner, John C Davis Jr, and Michael P Cooke.
View insider buying and selling activity for Magenta Therapeutics
.

Which major investors are buying Magenta Therapeutics stock?

MGTA stock was purchased by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Monashee Investment Management LLC, Alps Advisors Inc., Trexquant Investment LP, and State Board of Administration of Florida Retirement System.
View insider buying and selling activity for Magenta Therapeutics
.

How do I buy shares of Magenta Therapeutics?

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $7.18.

How big of a company is Magenta Therapeutics?

Magenta Therapeutics has a market capitalization of $346.46 million. The company earns $-76,770,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. Magenta Therapeutics employs 59 workers across the globe.

What is Magenta Therapeutics' official website?

The official website for Magenta Therapeutics is www.magentatx.com.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.